Best of the Blog: IN VIVO, April 2009
A selection of our favorite blog posts from April 2009 for stories not covered elsewhere in this month's IN VIVO. (See them for free at http://invivoblog.blogspot.com/).
You may also be interested in...
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.